<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03461575</url>
  </required_header>
  <id_info>
    <org_study_id>HU-007_P3</org_study_id>
    <nct_id>NCT03461575</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome</brief_title>
  <official_title>A Multicenter, Randomized, Double Blind, Restasis®-Controlled Non-inferiority, Moisview® Eye Drops-controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huons Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huons Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, Randomized, Double blind, Restasis®-controlled Non-inferiority, Moisview® Eye
      Drops-controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007
      Eye Drops in Patients with Dry Eye Syndrome
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 22, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from Baseline of Corneal staining score - Oxford grading</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from Baseline of Corneal staining score - Oxford grading</measure>
    <time_frame>Week 4,8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from Baseline of Conjunctival staining score - Oxford grading</measure>
    <time_frame>Week 4,8,12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from Baseline of Strip meniscometry assessment</measure>
    <time_frame>Week 4,8,12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from Baseline of Tear film break-up time</measure>
    <time_frame>Week 4,8,12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from Baseline of Standard patient evaluation of eye dryness questionnaire</measure>
    <time_frame>Week 4,8,12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arrival time of 100% clearence in Corneal staining test</measure>
    <time_frame>Week 0-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of total rescue drug usage</measure>
    <time_frame>Week 0-12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">213</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>HU007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine 0.02%, trehalose 3%
1 drop b.i.d at 12hr interval for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restasis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclosporine 0.05%
1 drop b.i.d at 12hr interval for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moisview</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>trehalose 3%
1 drop b.i.d at 12hr interval for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HU007</intervention_name>
    <description>cyclosporine 0.02%, trehalose 3%</description>
    <arm_group_label>HU007</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Restasis</intervention_name>
    <description>cyclosporine 0.05%</description>
    <arm_group_label>Restasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moisview</intervention_name>
    <description>trehalose 3%</description>
    <arm_group_label>Moisview</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age over 19

          -  Corneal staining score(Oxford grading) ≥ 2 or Schirmer test ≤ 10mm/5min (If Schirmer
             test = 0mm/5min, Nasal stimulation schirmer test ≥ 3mm/5min)

          -  Volunteer who went through menopause more than 1 years ago before screening or has
             surgical menopause or who has negative result of pregnancy test or use effective
             contraception

        Exclusion Criteria:

          -  The patients with systemic or ocular disorders affected the test result

          -  Current or recent patients used dry eye syndrome medications (topical or systemic)
             that may affect the status

          -  Being treated with systemic steroid

          -  Wearing contact lenses within 72 hr of screening visit

          -  Pregnancy or Breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-woon Hong</last_name>
    <role>Study Director</role>
    <affiliation>Huons Co.,Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Choun-Ki Joo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul ST.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

